EMA Authorised: Elaprase (idursulfase) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

The European Medicines Agency authorised Elaprase (idursulfase) for treatment of mucopolysaccharidosis type II (Hunter syndrome), with Takeda Pharmaceuticals In…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Ii

Drugs mentioned

• Elaprase (idursulfase)

Snippet

Status: Authorised. Therapeutic area: Mucopolysaccharidosis II. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 16/04/2025